Publication date: August 2016Source:Epilepsy & Behavior, Volume 61
Author(s): Laura E. Hernández-Vanegas, Aurelio Jara-Prado, Adriana Ochoa, Nayelli Rodríguez y Rodríguez, Reyna Durón, Daniel Crail-Meléndez, Ma. Elisa Alonso, Antonio V. Delgado-Escueta, Iris E. Martínez-Juárez
Juvenile myoclonic epilepsy (JME) is a genetic generalized epilepsy accounting for 3–12% of adult cases of epilepsy. Valproate has proven to be the first-choice drug in JME for controlling the most common seizure types: myoclonic, absence, and generalized tonic–clonic (GTC). In this retrospective study, we analyzed seizure outcome in patients with JME using valproate monotherapy for a minimum period of one year. Low valproate dose was considered to be 1000mg/day or lower, while serum levels were considered to be low if they were at or below 50mcg/dl. One hundred three patients met the inclusion criteria. Fifty-six patients (54.4%) were female. The current average age was 28.4±7.4years, while the age of epilepsy onset was 13.6±2.9years. Most patients corresponded to the subsyndrome of classic JME. Forty-six (44.7%) patients were free from all seizure types, and 76 (73.7%) patients were free from GTC seizures. No significant difference was found in seizure freedom among patients using a low dose of valproate versus a high dose (p=0.535) or among patients with low blood levels versus high blood levels (p=0.69). In patients with JME, it seems appropriate to use low doses of valproate (500mg to 1000mg) for initial treatment and then to determine if freedom from seizures was attained.
27
JUN
